LY2605541-A preferential hepato-specific insulin analogue

Diabetes

Volumn 63, Issue 2, 2014, Pages 390-392

  Madsbad, Sten ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN LISPRO; INSULIN PEGLISPRO; SOMATOMEDIN C RECEPTOR; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BINDING AFFINITY; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BINDING; DRUG HALF LIFE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLUCOSE TRANSPORT; HUMAN; HYDRODYNAMICS; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LIPID OXIDATION; LIPID STORAGE; LIPOLYSIS; MOLECULAR SIZE; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; OPEN STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN LISPRO; INSULINS; LIVER; POLYETHYLENE GLYCOLS;

EID: 84893041726     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-1646     Document Type: Note

References (14)

1. Owens DR, Matfin G, Monnier L. Basal insulin analogues in the management of diabetes mellitus: What progress have we made? Diabetes Metab Res Rev 11 September 2013 [Epub ahead of print]
2. Rendell M. Insulin degludec: a long-acting modern insulin analogue with a predictable pharmacokinetic/pharmacodynamic profile. Drugs Today (Barc) 2013;49:387-397
3. Moore MC, Smith MS, Sinha VP, et al. Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism. Diabetes 2014;63:494-504
4. Beals JM, Cutler GB, Doyle B, et al. Pegylated insulin lispro compounds. U.S. patent 20090312236 A1. 17 December 2009
5. Hansen RJ, Cutler GB, Vick A, et al. LY260541: leveraging hydrodynamic size to develop a novel basal insulin. Diabetes 2012;61(Suppl. 1):A228
6. Bergenstal RM, Rosenstock J, Arakaki RF, et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012;35:2140-2147
7. Rosenstock J, Bergenstal RM, Blevins TC, et al. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 patients: a randomized, crossover study. Diabetes Care 2013;36:522-528
8. Sinha VP, Howey DC, Kwang wei Soon D, et al. Single-dose pharmacokinetics (PK) and glucodynamics (GD) of the novel long-acting basal insulin LY2605541 in healthy subjects. Diabetes 2012;61(Suppl. 1): A273
9. Linnebjerg H, Choi SL, Lam ECQ, Mace KF, Hogson TS, Sinha VP. Pharmacokinetics (PK) of the novel, long-acting basal insulin LY2605541 in subjects with varying degrees of renal function. Diabetologia 2012;55 (Suppl. 1):S379
10. Heise T, Howey DC, Sinah VP, Choi SL, Mace KF. Steady-state pharmaocokinetics (PK) and glucodynamics (GD) of the novel, long-acting basal insulin LY2605541 dosed once-daily (OD) in patients with type 2 diabetes. Diabetes 2012;61(Suppl. 1):A256
11. Morrow LA, Hompesch M, Jacober SJ, Choi SL, Qu Y, Sinha V. LY2605541 exhibits a flatter glucodynamic profile than insulin glargine at steady state in subjects with type 1 diabetes. Diabetologia 2013;56(Suppl. 1): S556
12. Owens RA, Lockwood JF, Dunbar JD, et al. In vitro characterization of novel basal insulin LY2605541: reduced mitogenicity and IGF-IR binding. Diabetes 2012;61(Suppl. 1):A425
13. Madsbad S, Hilsted J, Krarup T, et al. The importance of plasma free insulin and counterregulatory hormones for recovery to normoglycemia following hypoglycemia in type 1 patients. Acta Endocrinol (Copenh) 1985; 108:224-230
14. Lecavalier L, Bolli G, Cryer P, Gerich J. Contributions of gluconeogenesis and glycogenolysis during glucose counterregulation in normal humans. Am J Physiol 1989;256:E844-E851